[Abstract] [Full Text PDF] (in Japanese / 1838KB) [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 92(9): 1225-1228, 1991


Report on the annual meeting

INTRATUMORAL INJECTION OF BIOLOGICAL RESPONSE MODIFIER (BRM)

Second Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan

Kiyoshi Nishiyama

Specific antitumor effects of lymphokine activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of IL-2 were studied. Furthermore, eff㏄ts of preoperative endoscopic intratumoral injection combined IL-2 and Lentinan or OK-432 were clinically studied against gastric cancer.
The results were as follows:
After intratumoral consecutive injection of recombinant human IL-2 (rhIL-2), the splenocytes of these mice were cultured with rhlL-2 and the effector cells were obtained.
1) Adoptive transfer of the effector cells specifically diminished the size of the host tumor and prolonged the life span of the mice.
2) The analysis of the surface antigens indicated the Thy1.2, Thy1.2+ L3T4+ cells increased in the effector cells as the specific cytotoxicity of them were augumented.
3) Preoperative endoscopic intratumoral injection combined IL-2 and Lentinan or OK-432 induced immuno-cytes including antigen-presenting cells in the site of the gastric cancer, and increased the IL-2R and the LAK activity of PBL. This method was considered as effective as an adjuvant treatment of gastric cancer surgery as a in vivo sensitization.


<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.